gliosarcoma (Cancer)
Information
- Disease name
- gliosarcoma
- Disease ID
- DOID:3071
- Description
- "A gliomablastoma that is characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation." [url:https\://en.wikipedia.org/wiki/Gliosarcoma, url:https\://www.cancer.gov/rare-brain-spine-tumor/tumors/gliosarcoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04216329 | Active, not recruiting | Phase 1 | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | July 7, 2020 | July 30, 2026 |
| NCT02152982 | Active, not recruiting | Phase 2/Phase 3 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | December 15, 2014 | December 15, 2024 |
| NCT03174197 | Active, not recruiting | Phase 1/Phase 2 | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | June 30, 2017 | June 30, 2025 |
| NCT04396860 | Active, not recruiting | Phase 2/Phase 3 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | September 1, 2020 | March 11, 2025 |
| NCT03137888 | Active, not recruiting | Phase 2 | Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma | September 20, 2017 | January 4, 2025 |
| NCT02455557 | Active, not recruiting | Phase 2 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | May 4, 2015 | December 30, 2024 |
| NCT03452930 | Active, not recruiting | Phase 1 | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma | August 13, 2018 | December 30, 2024 |
| NCT02101905 | Active, not recruiting | Phase 1 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | March 13, 2014 | October 19, 2024 |
| NCT01430351 | Active, not recruiting | Phase 1 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | September 14, 2011 | September 30, 2025 |
| NCT04397679 | Active, not recruiting | Phase 1 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma | August 12, 2021 | April 27, 2026 |
| NCT00597402 | Completed | Phase 2 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | July 2007 | May 2013 |
| NCT00609999 | Completed | Phase 1 | Ph I Dasatinib + Erlotinib in Recurrent MG | January 2008 | July 2010 |
| NCT00610571 | Completed | Phase 1 | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | April 2004 | April 2012 |
| NCT00611325 | Completed | Phase 2 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | May 2008 | October 2013 |
| NCT00612339 | Completed | Phase 2 | Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | August 2007 | May 2012 |
| NCT00612430 | Completed | Phase 2 | Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | March 2007 | September 2011 |
| NCT00612638 | Completed | Phase 1 | Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas | January 2005 | July 2008 |
| NCT00612651 | Completed | Phase 1 | PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | October 2005 | June 2011 |
| NCT00612989 | Completed | Phase 1 | Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | February 2005 | July 2008 |
| NCT00613028 | Completed | Phase 2 | Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | April 2008 | January 2011 |
| NCT00613054 | Completed | Phase 1 | Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | November 2007 | April 2009 |
| NCT00613132 | Completed | Phase 1 | Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG | May 2005 | January 2013 |
| NCT00613223 | Completed | Phase 1 | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | February 2008 | May 2011 |
| NCT00615927 | Completed | Phase 2 | Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | February 2006 | June 2012 |
| NCT00657267 | Completed | Phase 2 | Dose-Intense Temozolomide in Recurrent Glioblastoma | May 2008 | October 2013 |
| NCT00031083 | Completed | Phase 1 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | April 2, 2002 | October 10, 2003 |
| NCT00671970 | Completed | Phase 2 | Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | February 2007 | April 2010 |
| NCT00672243 | Completed | Phase 2 | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | April 2007 | December 2009 |
| NCT00734682 | Completed | Phase 1 | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | August 2008 | December 2014 |
| NCT00879437 | Completed | Phase 2 | Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | September 1, 2009 | October 2, 2017 |
| NCT00884416 | Completed | Phase 1 | Sorafenib in Newly Diagnosed High Grade Glioma | March 2009 | March 2012 |
| NCT00884741 | Completed | Phase 3 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | April 15, 2009 | March 17, 2013 |
| NCT00960492 | Completed | Phase 1 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | September 2009 | October 2013 |
| NCT00979017 | Completed | Phase 2 | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | November 2009 | January 2013 |
| NCT00995007 | Completed | Phase 2 | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | September 2009 | December 2015 |
| NCT01004874 | Completed | Phase 2 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | December 30, 2009 | November 2, 2021 |
| NCT01082926 | Completed | Phase 1 | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | May 2010 | September 2013 |
| NCT01113398 | Completed | Phase 2 | AMG 102 and Avastin for Recurrent Malignant Glioma | August 2010 | September 2015 |
| NCT00667394 | Completed | Phase 2 | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | April 2008 | July 2011 |
| NCT00087451 | Completed | Phase 1 | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) | July 2004 | November 2005 |
| NCT00100802 | Completed | Phase 2 | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas | March 21, 2005 | June 30, 2017 |
| NCT00107003 | Completed | Phase 2 | GW572016 to Treat Recurrent Malignant Brain Tumors | March 30, 2005 | November 30, 2012 |
| NCT00165477 | Completed | Phase 2 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | September 2005 | July 2009 |
| NCT00187486 | Completed | Phase 2 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | August 2004 | March 2011 |
| NCT00354913 | Completed | Phase 2 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | May 2005 | October 2010 |
| NCT00402116 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | September 2006 | December 2009 |
| NCT00441142 | Completed | Phase 1/Phase 2 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors | May 25, 2007 | October 10, 2017 |
| NCT00525525 | Completed | Phase 2 | Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | September 2007 | May 2013 |
| NCT01149850 | Completed | Phase 2 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | April 28, 2010 | December 8, 2023 |
| NCT01189266 | Completed | Phase 1/Phase 2 | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma | August 9, 2010 | September 30, 2021 |
| NCT01250470 | Completed | Phase 1 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | September 5, 2012 | May 29, 2014 |
| NCT01380782 | Completed | Phase 2 | BIBF 1120 for Recurrent High-Grade Gliomas | May 2012 | July 2014 |
| NCT01454596 | Completed | Phase 1/Phase 2 | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII | May 16, 2012 | January 17, 2019 |
| NCT01480479 | Completed | Phase 3 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | November 2011 | November 2016 |
| NCT01498328 | Completed | Phase 2 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | December 2011 | May 17, 2016 |
| NCT01514201 | Completed | Phase 1/Phase 2 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | February 1, 2012 | March 28, 2018 |
| NCT01609790 | Completed | Phase 2 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | June 4, 2012 | May 20, 2022 |
| NCT01740258 | Completed | Phase 2 | Bevacizumab Beyond Progression (BBP) | January 2013 | November 14, 2019 |
| NCT01856933 | Completed | Phase 2 | BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) | May 2013 | February 2015 |
| NCT01922076 | Completed | Phase 1 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | September 3, 2013 | September 30, 2022 |
| NCT01931098 | Completed | Phase 2 | Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | December 10, 2015 | September 12, 2019 |
| NCT01957956 | Completed | Early Phase 1 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | November 11, 2013 | November 16, 2016 |
| NCT01975116 | Completed | Phase 1 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | August 2013 | April 2015 |
| NCT02052648 | Completed | Phase 1/Phase 2 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | March 2014 | June 20, 2019 |
| NCT02311920 | Completed | Phase 1 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | April 16, 2015 | December 22, 2022 |
| NCT02386826 | Completed | Phase 1 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | September 22, 2015 | August 23, 2023 |
| NCT02502708 | Completed | Phase 1 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | October 2015 | February 28, 2020 |
| NCT02573324 | Completed | Phase 3 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification | January 4, 2015 | April 4, 2022 |
| NCT02658981 | Completed | Phase 1 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | August 24, 2016 | October 3, 2023 |
| NCT02661282 | Completed | Phase 1/Phase 2 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | June 1, 2016 | February 23, 2022 |
| NCT02709226 | Completed | Phase 1 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | June 15, 2016 | July 19, 2023 |
| NCT02798406 | Completed | Phase 2 | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | October 6, 2016 | June 30, 2021 |
| NCT02942264 | Completed | Phase 1/Phase 2 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | December 14, 2016 | August 26, 2020 |
| NCT03020017 | Completed | Early Phase 1 | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | May 25, 2017 | August 19, 2020 |
| NCT03020602 | Completed | Phase 1 | BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab | January 4, 2017 | June 26, 2021 |
| NCT03043391 | Completed | Phase 1 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | November 7, 2017 | March 23, 2022 |
| NCT04091503 | Completed | Phase 1 | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | December 20, 2019 | October 28, 2022 |
| NCT05756985 | Not yet recruiting | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | June 2024 | June 2028 | |
| NCT04528680 | Recruiting | Phase 1/Phase 2 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma | October 29, 2020 | September 2025 |
| NCT05095376 | Recruiting | Phase 3 | Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma | November 29, 2021 | August 8, 2031 |
| NCT04555577 | Recruiting | Phase 1 | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | September 20, 2020 | October 30, 2025 |
| NCT05698524 | Recruiting | Phase 1 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | June 26, 2023 | June 2027 |
| NCT05864534 | Recruiting | Phase 2 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | January 31, 2024 | August 2026 |
| NCT03107780 | Recruiting | Phase 1 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | July 9, 2018 | December 31, 2024 |
| NCT03115333 | Recruiting | N/A | DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma | July 25, 2017 | May 7, 2027 |
| NCT04817254 | Recruiting | Phase 2 | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | December 8, 2021 | December 31, 2026 |
| NCT03746080 | Recruiting | Phase 2 | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | December 4, 2018 | July 2027 |
| NCT05084430 | Recruiting | Phase 1/Phase 2 | Study of Pembrolizumab and M032 (NSC 733972) | February 25, 2022 | March 1, 2028 |
| NCT05091866 | Recruiting | Early Phase 1 | Natural Progesterone for the Treatment of Recurrent Glioblastoma | April 11, 2022 | August 25, 2026 |
| NCT01837862 | Recruiting | Phase 1/Phase 2 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | October 22, 2013 | April 2025 |
| NCT03197506 | Suspended | Phase 2 | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | September 15, 2017 | August 31, 2024 |
| NCT02168270 | Terminated | Phase 1 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | June 16, 2014 | August 20, 2015 |
| NCT00365222 | Terminated | Phase 2 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | July 2006 | June 2007 |
| NCT00735436 | Terminated | Phase 2 | A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | December 2008 | October 2012 |
| NCT00035373 | Terminated | Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols | April 19, 2002 | April 29, 2015 | |
| NCT02664363 | Terminated | Phase 1 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma | February 1, 2017 | September 12, 2019 |
| NCT02743078 | Terminated | Phase 2 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | May 9, 2017 | October 15, 2019 |
| NCT01186406 | Terminated | Phase 2 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | April 2011 | June 16, 2014 |
| NCT01227434 | Terminated | Phase 2 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma | September 2010 | December 2013 |
| NCT01095094 | Terminated | Phase 2 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | January 2009 | November 2011 |
| NCT01721577 | Terminated | Phase 1/Phase 2 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas | December 2012 | December 2015 |
| NCT01814813 | Terminated | Phase 2 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | May 2013 | May 1, 2023 |
| NCT01836549 | Terminated | Phase 2 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | March 2013 | April 2016 |
| NCT00669669 | Terminated | Phase 1/Phase 2 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | February 25, 2009 | January 20, 2021 |
| NCT03641326 | Terminated | Phase 2 | Sunitinib in Sarcomas of the Central Nervous System | February 21, 2019 | April 2, 2021 |
| NCT03843814 | Terminated | N/A | Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma | August 2014 | December 13, 2017 |
| NCT03973918 | Terminated | Phase 2 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG | July 29, 2019 | October 1, 2023 |
| NCT01086345 | Terminated | Early Phase 1 | Radiosurgery Plus Bevacizumab in Glioblastoma | February 2010 | December 2014 |
| NCT02133183 | Terminated | Phase 1 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | July 2, 2014 | October 31, 2023 |
| NCT00734526 | Terminated | Phase 1 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | December 18, 2008 | December 2012 |
| NCT00114309 | Unknown status | Phase 2 | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | November 2004 | August 2009 |
| NCT00936052 | Unknown status | Phase 2 | Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma | December 2008 | December 2010 |
| NCT01124539 | Unknown status | Phase 2 | Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma | December 2009 | February 2015 |
| NCT03401866 | Unknown status | N/A | Multi-site Validation and Application of a Consensus DSC-MRI Protocol | February 2018 | July 2021 |
| NCT01903330 | Unknown status | Phase 2 | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | March 2014 | March 2023 |
| NCT03275558 | Withdrawn | Phase 1 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | July 17, 2018 | July 17, 2018 |
| NCT03014804 | Withdrawn | Phase 2 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | December 1, 2019 | December 1, 2022 |
| NCT00734864 | Withdrawn | Phase 1 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | June 2009 | June 2012 |
| NCT02599090 | Withdrawn | Phase 2 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | December 2008 | December 2012 |
- Disase is a (Disease Ontology)
- DOID:3068
- Cross Reference ID (Disease Ontology)
- GARD:5653
- Cross Reference ID (Disease Ontology)
- ICDO:9442/3
- Cross Reference ID (Disease Ontology)
- MESH:D018316
- Cross Reference ID (Disease Ontology)
- NCI:C3796
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:35262004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206726
- Exact Synonym (Disease Ontology)
- Glioblastoma with sarcomatous component
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018316